Evidence map›Paper›PMID 16368976›Full record

ArticleInfection and immunity2006

Comparison of gamma interferon-mediated antichlamydial defense mechanisms in human and mouse cells.

Christine Roshick, Heidi Wood, Harlan D Caldwell, Grant McClarty

Abstract readComparative Study
In one paragraph

Article in Infection and immunity, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed.

  1. RNF213-dependent lytic destruction ofProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Journal of bacteriology · 2025
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. T cell responses to Chlamydia.Pathogens and disease · 2021
    Review
  13. Article
  14. Indoleamine 2,3-Dioxygenase Cannot InhibitFrontiers in immunology · 2021
    Article
  15. Article
  16. Article
  17. HowProceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  18. Antigen-Specific CD4Infection and immunity · 2019
    Article
  19. Article
  20. Indoleamine 2,3-Dioxygenase Activity inFrontiers in cellular and infection microbiology · 2019
    Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Christine RoshickNational Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3R2.
Heidi Wood
Harlan D Caldwell
Grant McClarty

Funding

Pathogensis of Chlamydial InfectionZIAAI000845 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CALDWELL, HARLAN D · 2009 to 2022
$14.8M
Chlamydial Immunity and Vaccine DevelopmentZIAAI000672 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CALDWELL, HARLAN D · 2009 to 2016
$6.8M
PATHOGENOMICS OF CHLAMYDIAL INFECTIONZ01AI000845 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI CALDWELL, HARLAN D · 1999 to 2008
$1.6M
MUCOSAL IMMUNITY TO CHLAMYDIAL INFECTIONZ01AI000672 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI CALDWELL, HARLAN D · 1993 to 2008
$1.4M
Chlamydia trachomatis, Genital Flora, &STD PathogenesisR21AI054875 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI BYRNE, GERALD IRWIN · 2003 to 2004
$375k
NIAID NIH HHS R21 AI054875NIAID NIH HHS R21 AI 054875-02
6 · The paper itself

Abstract

Gamma interferon (IFN-gamma)-induced effector mechanisms have potent antichlamydial activities that are critical to host defense. The most prominent and well-studied effectors are indoleamine dioxygenase (IDO) and nitric oxide (NO) synthase. The relative contributions of these mechanisms as inhibitors of chlamydial in vitro growth have been extensively studied using different host cells, induction mechanisms, and chlamydial strains with conflicting results. Here, we have undertaken a comparative analysis of cytokine- and lipopolysaccharide (LPS)-induced IDO and NO using an extensive assortment of human and murine host cells infected with human and murine chlamydial strains. Following cytokine (IFN-gamma or tumor necrosis factor alpha) and/or LPS treatment, the majority of human cell lines induced IDO but failed to produce NO. Conversely, the majority of mouse cell lines studied produced NO, not IDO. Induction of IDO in human cell lines inhibited growth of L2 and mouse pneumonitis agent, now referred to as Chlamydia muridarum MoPn equally in all but two lines, and inhibition was completely reversible by the addition of tryptophan. IFN-gamma treatment of mouse cell lines resulted in substantially greater reduction of L2 than MoPn growth. However, despite elevated NO production by murine cells, blockage of NO synthesis with the l-arginine analogue N-monomethyl-l-arginine only partially rescued chlamydial growth, suggesting the presence of another IFN-gamma-inducible antichlamydial mechanism unique to murine cells. Moreover, NO generated from the chemical nitric oxide donor sodium nitroprusside showed little direct effect on chlamydial infectivity or growth, indicating a natural resistance to NO. Finally, IFN-gamma-inducible IDO expression in human HeLa cells was inhibited following exogenous NO treatment, resulting in a permissive environment for chlamydial growth. In summary, cytokine- and LPS-inducible effectors produced by human and mouse cells differ and, importantly, these host-specific effector responses result in chlamydial strain-specific antimicrobial activities.

Indexed as

AnimalsCell LineCell Line, TumorChlamydia InfectionsChlamydia muridarumChlamydia trachomatisHeLa CellsHumansIndoleamine-Pyrrole 2,3,-DioxygenaseInterferon-gammaLipopolysaccharidesMiceNitric Oxide DonorsNitric Oxide Synthase Type IIIndoleamine-Pyrrole 2,3,-DioxygenaseInterferon-gammaLipopolysaccharidesNitric Oxide DonorsNitric Oxide Synthase Type II

Identifiers

PMID16368976
PMCPMC1346650

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.